Patents Represented by Attorney John R. Moore, Esq.

Find this attorney in the Justia Lawyer Directory

  • 6-oxo-1,6-dihydropyridine derivatives as inhibitors of MEK and methods of use thereof
    Patent number: 8211920
    Abstract: Disclosed are compounds of the Formula V and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, and W are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, and inflammatory conditions in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases and inflammatory conditions in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: August 5, 2008
    Date of Patent: July 3, 2012
    Assignee: Array BioPharma Inc.
    Inventors: Allison L. Marlow, Eli M. Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
  • 8-substituted benzoazepines as toll-like receptor modulators
    Patent number: 8153622
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: April 10, 2012
    Assignee: Array BioPharma Inc.
    Inventors: George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones
  • 6-oxo-1,6-dihydropyridine compounds as inhibitors of MEK and methods of use thereof
    Patent number: 8101639
    Abstract: Disclosed are compounds of the Formulas I and V and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: October 12, 2009
    Date of Patent: January 24, 2012
    Assignee: Array BioPharma Inc.
    Inventors: Allison L. Marlow, Eli M. Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong-Woon Yang, James Blake
  • Substituted pyridazines inhibitors of MEK
    Patent number: 8101611
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: January 24, 2012
    Assignee: Array BioPharma Inc.
    Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong woon Yang, James F. Blake
  • Kinase inhibitors and methods of use thereof
    Patent number: 8044083
    Abstract: The compound of Formula (I) and pharmaceutically acceptable salts and prodrugs thereof are useful in the treatment and prevention of various disorders mediated by kinases.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: October 25, 2011
    Assignee: Array BioPharma Inc.
    Inventors: Robert Groneberg, Laurence E. Burgess, Darren Harvey, Ellen Laird, Mark C. Munson, James P. Rizzi, Martha Rodriguez, Charles Todd Eary, Daniel John Watson
  • Process for preparing benzimidazole compounds
    Patent number: 8039637
    Abstract: Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ia-1 and their synthetic intermediates: wherein Z, X1, X2, X5, R2 and R10 are as defined herein. Compounds of Formula Ia-1 and their synthetic intermediates can be used to prepare heterocyclic derivatives such as benzimidazole derivatives.
    Type: Grant
    Filed: June 21, 2006
    Date of Patent: October 18, 2011
    Assignee: Array BioPharma Inc.
    Inventors: John DeMattei, Sagar Shakya, Anthony D. Piscopio, Bruno P. Hache, Matthew Charles Evans, James Gair Ford, Simon Mark Pointon, Koen Peeters, Timothy John Lilley, John Leonard
  • Kinase inhibitors and methods of use thereof
    Patent number: 8039639
    Abstract: A compound of Formula II and salts thereof are useful in the preparation of a compound of Formula I and pharmaceutically acceptable salts and prodrugs thereof.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: October 18, 2011
    Assignee: Array BioPharma Inc.
    Inventors: Robert Groneberg, Laurence E. Burges, Darren Harvey, Ellen Laird, Mark C. Munson, James P. Rizzi, Martha Rodriguez, Charles Todd Eary, Daniel John Watson
  • P38 inhibitors and methods of use thereof
    Patent number: 8026233
    Abstract: Compounds of formula (I): in which A, B, X, Ar1, R8 and R4 have any of the meanings given in the specification, are inhibitors of p38 useful in the treatment and prevention of various disorders mediated by p38.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: September 27, 2011
    Assignee: Array BioPharma Inc.
    Inventors: Mark C. Munson, Kevin W. Hunt, Christopher T. Clark, Ganghyeok Kim, Laurence E. Burgess, James P. Rizzi
  • P38 inhibitors and methods of use thereof
    Patent number: 8017641
    Abstract: This invention relates to inhibitors of p38 and methods of utilizing the inhibitors and pharmaceutical compositions thereof in the treatment and prevention of various disorders mediated by p38.
    Type: Grant
    Filed: February 2, 2009
    Date of Patent: September 13, 2011
    Assignee: Array BioPharma Inc.
    Inventors: Mark Munson, David A. Mareska, Youngboo Kim, Robert D. Gronenberg, James P. Rizzi, Martha Rodriguez, Ganghyeok Kim, Guy Vigers, Chang Rao, Devan Balachari, Darren Harvey
  • N3 alkylated benzimidazole derivatives as MEK inhibitors
    Patent number: 8003805
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: August 23, 2011
    Assignee: Array BioPharma Inc.
    Inventors: Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley